Tirzepatide + Cagrilintide Research Blend
70 mg total peptide
(60 mg tirzepatide / 10 mg cagrilintide)
Lyophilised peptides blended into a 3 ml liquid solution
Research use only

CagriTirz 70 mg usually comes into play once lower-level models stop explaining what’s actually happening.

Not because they’re wrong.
Because they’re incomplete.

At 60 mg, tirzepatide opens the system wide. Dual incretin signalling, lots of overlap, plenty going on all at once. Useful — but at this scale, behaviour can start to feel scattered.

Cagrilintide changes that.

It doesn’t reduce the signal.
It gives it edges.

A researcher summed it up during a project review:

“High-dose tirz alone was noisy. Adding cagri didn’t slow it down — it made it readable.”

That’s the reason this blend exists.

Why this ratio works at higher levels

With tirzepatide doing the heavy lifting, small variations tend to amplify over time. The 10 mg of cagrilintide acts as a regulator, not a competitor.

Researchers tend to use this blend when they’re trying to understand:

• why strong signalling still produces messy data
• how intake patterns spread when restraint is missing
• whether adding regulation tightens outcomes without killing scale

One behavioural scientist put it simply:

“The range narrowed. That was the win.”

What tends to show up later, not sooner

This isn’t a “first week” compound.

What researchers usually talk about after enough data has built up sounds more like:

• fewer extreme swings between sessions
  • meals ending earlier without sharp cut-offs
  • less time spent chasing anomalies
  • more repeatable day-to-day behaviour

A lab lead admitted during a review meeting:

“At first it felt dull. Then we realised it was stable.”

At this stage, stability is usually the goal.

About the 3 ml liquid solution

CagriTirz 70 mg is supplied as lyophilised peptides blended into a 3 ml liquid solution using bacteriostatic water.

Not for presentation.
For consistency.

When the biology is layered, preparation needs to stay boring. Fewer prep steps means fewer tiny differences creeping into long-run data.

One coordinator overseeing a multi-week protocol said it best:

“If the compound’s complicated, the format shouldn’t be.”

Where this blend usually fits

CagriTirz 70 mg doesn’t replace earlier work.

It usually comes after:

• GLP-1-only models
• tirzepatide-only studies
• lower-dose combination work

At that point, teams are often looking to see what happens when breadth is paired with restraint, rather than left unchecked.

An academic group described it during a seminar as:

“The point where tirzepatide starts behaving itself — even at scale.”

Not technical language. Still accurate.

Handling (standard practice)

• store refrigerated at 2–8 °C
  • do not freeze
  • protect from strong light
  • standard aseptic technique
  • follow documented research timelines

Nothing unusual.

Questions people actually ask

Is this stronger than lower-dose CagriTirz?
It’s broader. The regulation comes from cagri, not from reducing signal.

Does it act quickly?
Usually no. Meaningful patterns emerge over time.

Why keep cagrilintide at 10 mg?
Because increasing restraint doesn’t require increasing dominance.

Is this for human use?
No. Research only.

Who normally uses this blend?
Labs already comfortable with tirzepatide that want cleaner, more stable behavioural data at higher scale.

Compliance

Supplied only for laboratory research and analytical investigation.

Not a medicine.
Not for humans or animals.
Not for diagnosis or treatment.

Use lawfully and document everything.